Joel Cobb, MD
Family Medicine · North Little Rock, ARNPI 1124132485
Payments from drug & device makers
Across 116 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$341
- Abbott$298
- Pfizer$185
- AbbVie$170
- Lilly USA, LLC$140
- Johnson & Johnson$114
- plus $766 from 22 others
What the payments were for
- Food & beverage$2,015100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $341 |
| Abbott | 17 | $298 |
| Pfizer | 11 | $185 |
| AbbVie | 11 | $170 |
| Lilly USA, LLC | 8 | $140 |
| Johnson & Johnson | 5 | $114 |
| GSK | 5 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Genentech USA, Inc. | 1 | $82 |
| Paratek Pharmaceuticals, Inc. | 3 | $55 |
| Novo Nordisk | 3 | $46 |
| Astellas Pharma US Inc | 2 | $41 |
| Exact Sciences | 2 | $38 |
| Boston Scientific | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Merck | 2 | $31 |
| Dexcom, Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Shire North American Group Inc | 2 | $26 |
| Lundbeck LLC | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Amgen | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$2,015 in reported general payments places this provider in the 70th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $75,245 |
| OzempicSemaglutide | 83 | $72,648 |
| MounjaroTirzepatide | 52 | $51,181 |
| FarxigaDapagliflozin Propanediol | 58 | $47,816 |
| JardianceEmpagliflozin | 37 | $39,861 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $21,043 |
| JanuviaSitagliptin Phosphate | 19 | $16,939 |
| XareltoRivaroxaban | 14 | $15,940 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,706 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $7,101 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,067 |
| Atorvastatin Calcium | 511 | $5,831 |
| Rosuvastatin Calcium | 308 | $4,573 |
| Irbesartan | 136 | $4,231 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $4,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $185 | $78,103102 claims |
| Novo NordiskOzempic | $46 | $72,64883 claims |
| Lilly USA, LLCMounjaro | $140 | $51,18152 claims |
| AstraZenecaFarxiga | $341 | $47,81658 claims |
| Boehringer IngelheimJardiance | $15 | $39,86137 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $86 | $20,77337 claims |
| MerckJanuvia | $31 | $16,93919 claims |
| Johnson & JohnsonXarelto | $114 | $15,94014 claims |
| AbbVieSynthroid | $170 | $1,64546 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in North Little Rock
- Michael BerryNorth Little Rock$18K
- Richard HeckNorth Little Rock$13K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.